From a press release

The Almac Group, a contract development and manufacturing organization, recently broke ground on a $65-million expansion project at its North American headquarters in Souderton, Pa.

“I would like to thank all within the organization for playing their part in our success,” Alan Armstrong, Almac Group Chairman and CEO, said at the ceremony. “We are committed to reinvesting all our profits back into the business, and this expansion in Pennsylvania will play a vital part in our continued growth.”

The expansion will increase Almac Group’s footprint by 50 percent when it is finished in 2025. It will add 115,000 square feet to the facility. The new space will be used for Cold Chain Operations, Just-In-Time Processing, and Analytical Testing capabilities. Almac officials say that will help increase capacity for clients by 60 percent and add 355 new jobs by 2026.

“Almac is dedicated to ensuring we remain a global leader in our industry, giving our clients, and ultimately patients, across the world the best possible offering,” Armstrong said. “We continue to play our part as a valued and trusted member of the communities in which we operate.”

Almac officials promise to follow U.S. Green Building Council LEED standards on cost-saving green buildings focused on efficiency and carbon reduction. It’s part of the company’s plan to have net-zero emissions by 2045. That initiative was announced last November as part of its Corporate Social Responsibility report.

Part of those environmental safeguard plans includes the building of a 140-foot pedestrian bridge that company officials say will bring greater walkability for guests and employees while also minimizing the environmental impact.

In keeping things within the Montgomery County ecosystem, Almac will use Blue Bell’s Cyma Builders & Construction Managers for the project. Cyma has a wide portfolio of work on R&D, infrastructure, and lab development.

Almac is best known for helping biopharma companies with services like research and development, clinical trial supply services, and API manufacturing. Founded in 2002 by the late Sir Allen McClay, Almac saw rapid growth across the globe. The Souderton facility opened in 2011.

The company is owned by The McClay Foundation, a North Ireland-based charity focused on R&D in new medicines, oncology research, and promoting “health and wellbeing in disenfranchised communities.”

Almac also has Pharmaceutical Development, Analytical and Solid State, Commercial, and Sales and Marketing services in Audubon and a Clinical Technologies location in Lansdale.